Based on Kaplan–Meier analysis, the survival time for infliximab is comparatively longer than that for adalimumab; however, there are no significant differences between the two drugs based on retention rate, with their efficacy diminishing over time. Psoriasis can be described as a chronic immune-mediated disorder that requires lifelong treatment. A drug’s survival and retention rates...